(VIANEWS) – Capital Product Partners L.P. (CPLP), Chubb Corporation (CB), FTI Consulting (FCN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Capital Product Partners L.P. (CPLP)
38.3% sales growth and 8.7% return on equity
Capital Product Partners L.P., a shipping company, provides marine transportation services in Greece. Its vessels transports a range of dry cargoes and containerized goods under short-term voyage charters, and medium to long-term time and bareboat charters. As of April 26, 2021, the company owned 17 vessels, including thirteen Neo-Panamax container vessels, three Panamax container vessels, and one Capesize bulk carrier. Capital GP L.L.C. serves as the general partner of the company. The company was incorporated in 2007 and is headquartered in Piraeus, Greece.
Earnings Per Share
As for profitability, Capital Product Partners L.P. has a trailing twelve months EPS of $2.71.
PE Ratio
Capital Product Partners L.P. has a trailing twelve months price to earnings ratio of 6.59. Meaning, the purchaser of the share is investing $6.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.7%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 32.9%, now sitting on 344.97M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 38.8% and positive 53.1% for the next.
2. Chubb Corporation (CB)
10.3% sales growth and 15.78% return on equity
Chubb Limited provides insurance and reinsurance products worldwide. The company's North America Commercial P&C Insurance segment offers commercial property, casualty, workers' compensation, package policies, risk management, financial lines, marine, construction, environmental, medical, cyber risk, surety, and excess casualty; and group accident and health insurance to large, middle market, and small commercial businesses. Its North America Personal P&C Insurance segment provides affluent and high net worth individuals and families with homeowners, automobile and collector cars, valuable articles, personal and excess liability, travel insurance, and recreational marine insurance and services. The company's North America Agricultural Insurance segment offers multiple peril crop and crop-hail insurance; and coverage for farm and ranch property, and commercial agriculture products. Its Overseas General Insurance segment provides coverage for traditional commercial property and casualty; specialty categories, such as financial lines, marine, energy, aviation, political risk, and construction risk; and group accident and health, and traditional and specialty personal lines for corporations, middle markets, and small customers through retail brokers, agents, and other channels. The company's Global Reinsurance segment offers traditional and specialty reinsurance under the Chubb Tempest Re brand to property and casualty companies. Its Life Insurance segment provides protection and savings products comprising whole life, endowment plans, individual term life, group term life, medical and health, personal accident, credit life, universal life, and unit linked contracts. It markets its products primarily through insurance and reinsurance brokers. The company was formerly known as ACE Limited and changed its name to Chubb Limited in January 2016. Chubb Limited was incorporated in 1985 and is headquartered in Zurich, Switzerland.
Earnings Per Share
As for profitability, Chubb Corporation has a trailing twelve months EPS of $21.81.
PE Ratio
Chubb Corporation has a trailing twelve months price to earnings ratio of 11.43. Meaning, the purchaser of the share is investing $11.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.78%.
Volume
Today’s last reported volume for Chubb Corporation is 1558160 which is 21.13% below its average volume of 1975620.
Moving Average
Chubb Corporation’s value is above its 50-day moving average of $228.92 and way higher than its 200-day moving average of $209.38.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Dec 13, 2023, the estimated forward annual dividend rate is 3.44 and the estimated forward annual dividend yield is 1.39%.
3. FTI Consulting (FCN)
10.2% sales growth and 13.72% return on equity
FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. The company operates through five segments: Corporate Finance & Restructuring, Forensic and Litigation Consulting, Economic Consulting, Technology, and Strategic Communications. Its Corporate Finance & Restructuring segment provides business transformation, transactions, and turnaround and restructuring services. The company's Forensic and Litigation Consulting segment offers. construction and environmental solution, data and analytics, dispute, health solution, and risk and investigation services. Its Economic Consulting segment provides. antitrust and competition economic, financial economic, and international arbitration services. The company's Technology segment offers corporate legal operation; e-discovery and expertise; and information governance, privacy, and security services. Its Strategic Communications segment provides corporate reputation, financial communication, and public affairs services. The company serves aerospace and defense, agriculture, airlines and aviation, automotive and industrial, construction, energy, power and products, environmental solutions, financial services, healthcare and life sciences, hospitality, gaming and leisure, insurance, mining, private equity, public sector, real estate, retail and consumer products, telecom, media and technology, and transportation and logistics industries. The company was founded in 1982 and is headquartered in Washington, District of Columbia.
Earnings Per Share
As for profitability, FTI Consulting has a trailing twelve months EPS of $6.77.
PE Ratio
FTI Consulting has a trailing twelve months price to earnings ratio of 29.3. Meaning, the purchaser of the share is investing $29.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.72%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 9.9% and 38.8%, respectively.
4. American National Bankshares (AMNB)
9% sales growth and 7.87% return on equity
American National Bankshares Inc. operates as the bank holding company for American National Bank and Trust Company that provides financial products and services in Virginia and North Carolina. The company operates through two segments, Community Banking, and Trust and Investment Services. It accepts deposit products, including checking, money market, savings, and consumer and commercial time deposits, as well as certificates of deposit. The company's loan products comprise commercial and residential real estate loans, commercial loans to small and medium-sized businesses, construction and land development loans, home equity loans, mortgage loans, and consumer loans. It also offers trust and investment services, such as estate planning, trust account administration, and retail brokerage services; online and telephone banking services; insurance services; and investment management services, including purchasing equity, fixed income, and mutual fund investments for customer accounts, as well as operates 37 automated teller machines. As of December 31, 2020, it operated 26 banking offices; and one loan production offices in Roanoke, Virginia. American National Bankshares Inc. was founded in 1909 and is headquartered in Danville, Virginia.
Earnings Per Share
As for profitability, American National Bankshares has a trailing twelve months EPS of $2.46.
PE Ratio
American National Bankshares has a trailing twelve months price to earnings ratio of 19.34. Meaning, the purchaser of the share is investing $19.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.87%.
5. Allegion plc Ordinary Shares (ALLE)
6.4% sales growth and 55.05% return on equity
Allegion plc manufactures and sells mechanical and electronic security products and solutions worldwide. The company offers door closers and controls; doors and door systems; electronic security products; electronic, biometric and mobile access control systems; exit devices; locks, locksets, portable locks, and key systems; time, attendance, and workforce productivity systems; and other accessories. The company sells its products and solutions to end-users in commercial, institutional, and residential facilities, including education, healthcare, government, hospitality, commercial office, and single and multi-family residential markets under the CISA, Interflex, LCN, Schlage, SimonsVoss, and Von Duprin brands. It sells its products and solutions through distribution and retail channels, such as specialty distribution, e-commerce, and wholesalers, as well as through various retail channels comprising do-it-yourself home improvement centers, on-line and e-commerce platforms, and small specialty showroom outlets. Allegion plc was incorporated in 2013 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Allegion plc Ordinary Shares has a trailing twelve months EPS of $6.32.
PE Ratio
Allegion plc Ordinary Shares has a trailing twelve months price to earnings ratio of 19.84. Meaning, the purchaser of the share is investing $19.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 55.05%.
Volume
Today’s last reported volume for Allegion plc Ordinary Shares is 725146 which is 14.64% below its average volume of 849531.
Sales Growth
Allegion plc Ordinary Shares’s sales growth is 4.8% for the present quarter and 6.4% for the next.
6. ResMed (RMD)
6.2% sales growth and 21.66% return on equity
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, ResMed has a trailing twelve months EPS of $6.04.
PE Ratio
ResMed has a trailing twelve months price to earnings ratio of 31.64. Meaning, the purchaser of the share is investing $31.64 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.66%.
Yearly Top and Bottom Value
ResMed’s stock is valued at $191.13 at 19:22 EST, way below its 52-week high of $243.52 and way higher than its 52-week low of $132.24.
7. STERIS (STE)
5.4% sales growth and 9.17% return on equity
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Earnings Per Share
As for profitability, STERIS has a trailing twelve months EPS of $5.51.
PE Ratio
STERIS has a trailing twelve months price to earnings ratio of 40.14. Meaning, the purchaser of the share is investing $40.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.17%.
8. Incyte Corporation (INCY)
5.3% sales growth and 9.28% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $1.88.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 30.94. Meaning, the purchaser of the share is investing $30.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 85.5% and 135.1%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Incyte Corporation’s EBITDA is 37.38.
